新候选抑癌基因DLC2在乳腺癌中的表达及临床病理学意义
Expression of Tumor Suppressor Candidate DLC2 in Breast Cancer and Its Clinicopathological Significance
目的：探讨新候选抑癌基因DLC2在乳腺癌中的表达和临床病理特征之间的关系。方法：收集131例乳腺癌及癌旁组织石蜡标本制作组织芯片，采用免疫组织化学二步法检测DLC2蛋白表达水平；收集3例乳腺癌及癌旁新鲜组织，通过western blotting进行验证；统计学分析DLC2表达水平与临床病理相关参数的关联。结果：DLC2在癌旁乳腺组织中表达阳性率为79.39%，阴性率20.61%；在乳腺癌组织中阳性率为42.75%，阴性率57.25%；两组间有统计学差异（P=0.000）。DLC2在无淋巴结转移乳腺癌组的表达阴性率为36.59%，有淋巴结转移组阴性率91.84%，两组间有统计学差异（P=0.000）。在乳腺癌新鲜组织中，DLC2蛋白的表达低于癌旁组织。结论：DLC2在乳腺癌中低表达,且与淋巴结高转移率关系密切相关，提示其可能在乳腺癌的发生发展中起抑癌基因作用。
In this paper, we detected the expression of DLC2 in human breast cancer and discussed its clinicopathological significance. 131 cases of breast cancer paraffin embeded tissues were collected and made into tissue microarray. 3 cases of breast cancer and peripheral normal fresh tissues were collected. We detected the expression of DLC2 by immunohistochemical staining in tissue microarray, or by western blotting in fresh tissues. We also analyzed the relationship between DLC2 expression level and tumor clinicopathological parameters. We found DLC2 was low expressed in breast cancer. The lower expression of DLC2 in breast cancer tissue was closely associated with high lymph node metastasis. These indicated DLC2 maybe play a tumor suppressor role in breast cancer.
林原、杨峥、薛玲、陈汉锐
肿瘤学基础医学临床医学
乳腺癌LC2抑癌基因组织芯片
breast cancerDLC2tumor suppressor genetissue chip
林原,杨峥,薛玲,陈汉锐.新候选抑癌基因DLC2在乳腺癌中的表达及临床病理学意义[EB/OL].(2016-05-18)[2025-08-02].http://www.paper.edu.cn/releasepaper/content/201605-570.点此复制
评论